The Latest Breaking News from FDA

Despite a slowdown of Covid-19 vaccine sales in the last reported quarter, biopharmaceutical giant Pfizer (PFE) is positioned to deliver robust growth this year and beyond, thanks to the strength of its in-line products and expected near-term launches and revenue distribution from the recent acquisition. So, let’s find out if…

Ozempic is a once-weekly injection used for the treatment of type 2 diabetes, though some of its side effects include weight loss

Ozempic is a once-weekly injection used for the treatment of type 2 diabetes, though some of its side effects include weight loss

A broader market rally is a reason to be bullish long term, but the Fed meeting is one reason to be cautious now. Biogen jumped late Friday. Watch Tesla and Nvidia.

Leqembi could become the first treatment of its kind to receive traditional approval from the FDA.

U.S. health advisers are backing the full approval of an Alzheimer's drug that received preliminary approval last year

Biogen stock rose Monday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.

The FDA could approve Crispr Therapeutics' gene-edited sickle cell treatment as early as December. In response, CRSP stock surged Friday.

A panel of experts to the Food and Drug Administration has recommended the agency approve a long-acting antibody drug that can protect infants from the seasonal virus, RSV.